Highest-materiality recent filing
Illumina appoints Eli Lilly's CSO Daniel Skovronsky to Board effective June 16, 2026
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board effective June 16, 2026; Board expanded to 10 members.
All nine director nominees elected; Anna Richo received 8.4M against votes (6.5% of votes cast).
Illumina Q1 revenue up 4.8% to $1.09B; non-GAAP EPS $1.15, raises FY2026 guidance; new $1.5B buyback
Revenue $1.09B (+4.8% YoY); GAAP EPS $0.87, non-GAAP EPS $1.15 vs prior year $0.97.
Illumina names David King to board; three directors to retire in May 2026
Drs. Frances Arnold, Robert Epstein, and Gary Guthart will retire as directors effective May 21, 2026.
Illumina Q4 revenue $1.16B (+5%), GAAP EPS $2.16; guides FY2026 rev $4.5-$4.6B
Revenue $1.16B in Q4 2025, up 5% YoY; ex-China revenue up 8%.
Illumina completes $350M acquisition of SomaLogic from Standard BioTools
Purchase price $350M in cash plus up to $75M in performance milestones and royalties.
Illumina prelim Q4 rev $1.155B (+5% YoY); FY rev flat at $4.34B; EPS ranges given
Q4 revenue ~$1.155B, up 5% YoY (4% constant currency); ex-China rev ~$1.1B up 7%.
Illumina appoints Dr. Eric Green as CMO; CCO Everett Cunningham resigns
Dr. Eric Green (former NHGRI director) named Chief Medical Officer, effective Feb 2, 2026.
Illumina closes $500M 4.750% notes due 2030; proceeds for refinancing and SomaLogic acquisition
Closed $500M public offering of 4.750% notes due December 12, 2030, issued under existing indenture.
Issued $500M aggregate principal of 4.750% notes due 2030 via underwriters Goldman Sachs & Co. LLC and BofA Securities.
Illumina Q3 revenue $1.08B flat YoY, non-GAAP EPS $1.34 beats; raises FY EPS guidance to $4.65-$4.75
Q3 GAAP diluted EPS $0.98, non-GAAP diluted EPS $1.34; non-GAAP operating margin 24.5%.
Illumina Q2 EPS $1.19 non-GAAP, revenue $1.06B; raises FY2025 guidance
Revenue $1.059B down 3% YoY; GAAP EPS $1.49, non-GAAP EPS $1.19 vs. $1.09 prior year.
Illumina to acquire SomaLogic for $350M cash plus up to $75M milestones
Illumina will acquire SomaLogic's aptamer-based proteomics business from Standard BioTools for $350M cash at closing, plus up to $75M in milestones and royalties.
Illumina stockholders approve amended equity plan adding ~6.3M shares
Stockholders approved the Second Amended and Restated 2015 Stock and Incentive Plan, adding up to 6.3M new shares plus carryover from prior plan.
Illumina Q1 core rev $1.04B (-1% YoY) but cuts FY2025 guidance on tariffs & China
GAAP diluted EPS $0.82; non-GAAP $0.97; GAAP op margin 15.8%, non-GAAP 20.4%.
Dr. Scott Gottlieb elected non-executive Chair of Illumina's Board, effective March 28, 2025.
Illumina CIO Carissa Rollins to retire effective April 11, 2025
CIO Carissa Rollins notified Illumina on March 18, 2025 of her retirement.
Illumina responds to China export ban, cuts FY2025 EPS guidance to ~$4.50
China MOFCOM prohibited Illumina from exporting sequencing instruments into China effective March 4, 2025.
Illumina Q4 core revenue up 1% to $1.1B; FY2025 guided to low single-digit growth
Core Illumina Q4 revenue $1.104B (+1% YoY); GAAP EPS $0.73, non-GAAP EPS $0.95.
Illumina records $14M additional impairment on San Diego property in Q4 2024
Total $32M impairment in Q1 2024 from exiting Foster City campus and another San Diego property.
Illumina reports Q4 core revenue $1.10B (+1% YoY); FY2025 outlook low-single-digit growth
FY2024 core revenue $4.33B (-2% YoY constant currency); Q4 revenue $1.10B (+1% YoY).
Illumina Q3 Core revenue $1.08B (-2% YoY); raises FY24 non-GAAP EPS guide to $4.05-$4.15
Core Illumina revenue $1.08B, down 2% YoY; GAAP diluted EPS $4.03, non-GAAP $1.14.
Illumina General Counsel Charles Dadswell to exit; Scott Davies named interim GC
Dadswell steps down as General Counsel and Secretary effective Oct 3, 2024; serves as advisor to CEO/Board through Mar 31, 2025.
Illumina repays $761M credit facility, issues $500M 4.650% notes due 2026
Repaid all $761M outstanding under 364-day delayed draw credit agreement on Sept 9, 2024.
Illumina prices $500M of 4.650% notes due 2026; proceeds to repay GRAIL spin-off debt
$500M aggregate principal of 4.650% notes maturing 2026 in an underwritten public offering.
Illumina Q2 core revenue $1.09B (-6% YoY); lowers FY2024 guidance
Core Illumina Q2 revenue $1.09B, down 6% YoY and 6% constant currency; up 3% from Q1.
Illumina completes GRAIL spin-off; expects $1.9B in Q2 impairment charges
Spin-off closed June 24, 2024; Illumina distributed 85.5% of GRAIL shares (1-for-6 ratio) and retained 14.5% stake.
Illumina estimates $1.466B goodwill and $420M IPR&D impairment charges for GRAIL in Q2 2024
Goodwill impairment charge of $1,466M related to GRAIL, representing full remaining carrying value as of March 31, 2024.
Illumina completes spin-off of GRAIL, retains 14.5% stake; GRAIL to trade as GRAL
Spin-off effective June 24, 2024: Illumina distributed 85.5% of GRAIL shares (1 share GRAIL per 6 shares ILMN), retains 14.5%.
Illumina enters $750M 364-day delayed draw credit facility for GRAIL divestiture funding
Credit facility of $750 million entered June 17, 2024, with JPMorgan as administrative agent.
Illumina clarifies GRAIL spin-off dates: distribution effective June 24, 2024
Distribution effective 12:01 A.M. NYC time on June 24; GRAIL begins regular-way trading June 25 under ticker GRAL.
Illumina board approves GRAIL spin-off; distribution set for June 24, 2024
Holders receive 1 GRAIL share per 6 Illumina shares held at close on June 13, 2024 (record date).
Illumina shareholders elect all 11 director nominees, ratify auditor, approve say-on-pay
All 11 director nominees elected; Jacob Thaysen received highest support with 130.2M votes for.
Illumina records $75M in impairments on Foster City, San Diego campus exits; $142M assets at risk
Recorded $43M right-of-use asset and leasehold improvement impairment in Q4 2023 for Foster City campus exit.
Illumina Q1 2024: Core rev -2% to $1.06B; GAAP loss $0.79; GRAIL divestiture on track
Core Illumina revenue $1.06B, down 2% YoY; GAAP operating margin 11.0%, non-GAAP 20.6%.
EC approves Illumina's GRAIL divestment plan; $1B funding requirement for capital markets option
European Commission formally approved Illumina's Divestment Plan for GRAIL, LLC, per October 2023 divestment order.
Illumina names Ankur Dhingra CFO; Joydeep Goswami departs; Q1/FY24 guidance reaffirmed
Ankur Dhingra appointed CFO effective April 15, 2024; previously CFO of Summit Therapeutics (SMMT) and CareDx.
Illumina Q4 rev $1.12B (+4% YoY), GAAP EPS $(1.11), non-GAAP $0.14; FY guide flat
Q4 revenue $1.12B, up 4% YoY (4% constant currency); GAAP gross margin 60.1%.
Illumina estimates $43M impairment charge for Foster City campus exit in Q4 2023
Right-of-use asset and leasehold improvement impairment charges estimated at $43M for Q4 2023.
Illumina Q4 rev $1.115B (+3%), FY rev $4.497B (-2%); shipped 352 NovaSeq X in FY23
Consolidated revenue $1,115M Q4 (+3% YoY); full-year $4,497M (-2% YoY).
Illumina CCO Susan Tousi departs; Bas Verhoef named interim CCO
Susan Tousi, Chief Commercial Officer, leaves Illumina effective January 5, 2024.
Illumina incurs $54M impairment charge for i3 campus exit; Foster City charges pending
Incurred ~$54M in right-of-use asset and leasehold impairment charges in 2023 for exiting i3 campus in San Diego.
Amended offer letter dated Nov 8, 2023 extends matching RSU purchase window from 90 days to 12 months after start date of Sept 25, 2023.
Illumina Q3 GAAP loss $4.77/sh on $821M GRAIL impairment; cuts FY2023 guidance
Revenue $1.12B flat YoY; GAAP diluted loss per share $(4.77) includes $821M GRAIL goodwill impairment.
Illumina decides to hold annual advisory votes on executive compensation until 2029
Following May 25, 2023 shareholder vote, company will continue annual say-on-pay votes.
Illumina CMO Phil Febbo departs; separation agreement provides $600K salary continuation
Chief Medical Officer Phil Febbo departed on August 7, 2023.
Illumina appoints Jacob Thaysen as permanent CEO effective Sept 25, 2023
Jacob Thaysen, formerly SVP at Agilent, named CEO and Board member starting Sept 25.
Revenue $1.176B (+1% YoY, +8% QoQ); GAAP loss per share $(1.48) vs $(3.40) (incl. $609M legal contingency).
Illumina CMO Phil Febbo departs Aug 7; CTO Alex Aravanis departs Aug 9, replaced by Steven Barnard
Dr. Phil Febbo, Chief Medical Officer, departed Illumina on August 7, 2023.
Illumina interim CEO Dadswell gets $50k/month stipend, bonus raised to 100%
Board approved $50,000 per month stipend for Charles Dadswell retroactive to June 1, 2023, through month permanent CEO appointed.
On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately.
On March 25, 2025, Stephen P. MacMillan, notified the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) of his intention to resign as a director of the Company, effective as of March 28, 2025.
On March 25, 2025, the Board elected Keith A. Meister to serve on the Board beginning March 28, 2025.
On March 18, 2025, Carissa Rollins, Chief Information Officer, notified Illumina, Inc. that she will be retiring effective as of April 11, 2025.
Charles Dadswell, the Company’s General Counsel and Secretary, will leave Illumina.
As of the Effective Date, Scott Davies, Vice President, Legal – Chief Corporate Counsel and Assistant Secretary, will serve as Interim General Counsel and Secretary.
Ankur Dhingra has been appointed Chief Financial Officer of the Company, effective April 15, 2024
Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.
Bas Verhoef, Head of Region – Europe, will serve as Interim Chief Commercial Officer
Susan Tousi, Chief Commercial Officer, will be leaving the Company effective as of January 5, 2024
Phil Febbo, Chief Medical Officer, departed the company on August 7, 2023.
Mr. Dadswell will continue to serve as the Company’s Senior Vice President and General Counsel following the Commencement Date.
Max materiality 0.90 · Median 0.68 · Most common event earnings